文献速递认知障碍与痴呆

使用氟美他莫F18标记正电子发射断层扫描及其他生物标志物评估遗忘型轻度认知障碍患者临床进展风险

Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
PubMed 文献 · JAMA Neurol · 2018-01-01

这项多中心队列研究纳入232例遗忘型轻度认知障碍患者,基线行氟美他莫F18 PET扫描并随访至36个月。PET阳性者进展为很可能阿尔茨海默病的风险比为2.51(95%CI 1.57-3.99;P<.001),合并海马体积低时风险比为5.60,再加入认知状态后风险比为8.45。

要点

  • 36个月时总体进展为很可能阿尔茨海默病的比例为36.2%(81/224)。
  • PET阳性患者进展率为53.6%(52/97),PET阴性患者为22.8%(29/127)。
  • PET阳性合并海马体积低及认知状态差时进展风险比达8.45(95%CI 4.40-16.24;P<.001)。

核心结论

  • 氟美他莫F18 PET阳性、海马体积低和认知状态三者组合与36个月内从遗忘型轻度认知障碍进展为很可能阿尔茨海默病的高概率风险相对应。

研究设计与样本

  • 多中心队列研究,2009年11月11日至2014年1月16日从欧洲和美国28个临床中心筛查365例遗忘型轻度认知障碍患者,232例符合条件入组。
  • 基线行氟美他莫F18 PET扫描,随后每6个月进行局部临床评估,最长3年,最多6次临床访视,并包含磁共振成像和多项认知测量。
  • 医生对PET结果严格设盲,标准真相由独立临床裁定委员会确认或否定局部评估;PET扫描由5名对临床状态不知情的盲法阅片者集中判读为阴性或阳性。
  • 统计分析于2014年2月19日至2018年1月26日进行。

主要发现

  • 232例遗忘型轻度认知障碍患者(118名女性,114名男性;平均[SD]年龄71.1[8.6]岁)中,98例(42.2%)PET扫描结果为阳性。
  • 36个月时,进展为很可能阿尔茨海默病的比例总体为36.2%(81/224例),PET阳性患者为53.6%(52/97例),PET阴性患者为22.8%(29/127例)。
  • 与进展相关的风险比:单纯β-淀粉样蛋白扫描阳性(主要结局指标)为2.51(95%CI 1.57-3.99;P<.001)。
  • 附加海马体积低时风险比为5.60(95%CI 3.14-9.98;P<.001)。
  • 在模型中再加入较差认知状态时风险比为8.45(95%CI 4.40-16.24;P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with amnestic mild cognitive impairment (aMCI) may progress to clinical Alzheimer disease (AD), remain stable, or revert to normal. Earlier progression to AD among patients who were β-amyloid positive vs those who were β-amyloid negative has been previously observed. Current research now accepts that a combination of biomarkers could provide greater refinement in the assessment of risk for clinical progression. OBJECTIVE: To evaluate the ability of flutemetamol F 18 and other biomarkers to assess the risk of progression from aMCI to probable AD. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter cohort study, from November 11, 2009, to January 16, 2014, patients with aMCI underwent positron emission tomography (PET) at baseline followed by local clinical assessments every 6 months for up to 3 years. Patients with aMCI (365 screened; 232 were eligible) were recruited from 28 clinical centers in Europe and the United States. Physicians remained strictly blinded to the results of PET, and the standard of truth was an independent clinical adjudication committee that confirmed or refuted local assessments. Flutemetamol F 18-labeled PET scans were read centrally as either negative or positive by 5 blinded readers with no knowledge of clinical status. Statistical analysis was conducted from February 19, 2014, to January 26, 2018. INTERVENTIONS: Flutemetamol F 18-labeled PET at baseline followed by up to 6 clinical visits every 6 months, as well as magnetic resonance imaging and multiple cognitive measures. MAIN OUTCOMES AND MEASURES: Time from PET to probable AD or last follow-up was plotted as a Kaplan-Meier survival curve; PET scan results, age, hippocampal volume, and aMCI stage were entered into Cox proportional hazards logistic regression analyses to identify variables associated with progression to probable AD. RESULTS: Of 232 patients with aMCI (118 women and 114 men; mean [SD] age, 71.1 [8.6] years), 98 (42.2%) had positive results detected on PET scan. By 36 months, the rates of progression to probable AD were 36.2% overall (81 of 224 patients), 53.6% (52 of 97) for patients with positive results detected on PET scan, and 22.8% (29 of 127) for patients with negative results detected on PET scan. Hazard ratios for association with progression were 2.51 (95% CI, 1.57-3.99; P < .001) for a positive β-amyloid scan alone (primary outcome measure), 5.60 (95% CI, 3.14-9.98; P < .001) with additional low hippocampal volume, and 8.45 (95% CI, 4.40-16.24; P < .001) when poorer cognitive status was added to the model. CONCLUSIONS AND RELEVANCE: A combination of positive results of flutemetamol F 18-labeled PET, low hippocampal volume, and cognitive status corresponded with a high probability of risk of progression from aMCI to probable AD within 36 months.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Wolk DA, Sadowsky C, Safirstein B, et al. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment. JAMA Neurol. 2018. PMID: 29799984. doi:10.1001/jamaneurol.2018.0894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。